Top Markets
Coin of the day
EFFECTOR Therapeutics, Inc. EFFECTOR Therapeutics, Inc.

EFFECTOR Therapeutics, Inc.

EFTRW
Hisse Senetlerindeki Sıralama #42260
eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the... eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.
Hisse Fiyatı
$0.0006
Son senkronizasyon: 2025-11-25
Piyasa Değeri
$2.82K
Değişim (1 gün)
59,900.00%
Değişim (1 yıl)
59,900.00%
Ülke
US
Ticaret EFFECTOR Therapeutics, Inc. (EFTRW)

Kategori

EFFECTOR Therapeutics, Inc. (EFTRW) için EPS
2026 itibariyle EPS TTM: 0
EFFECTOR Therapeutics, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
EFFECTOR Therapeutics, Inc. için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS